Followers | 230 |
Posts | 14589 |
Boards Moderated | 1 |
Alias Born | 03/29/2014 |
Thursday, June 14, 2018 9:16:11 PM
Thanks Lykiri, for posting this!
The paper that interested me the most was the response to consult and the commentator comments on the draft remit and draft scope (pre-referral).
This is the link...
https://www.nice.org.uk/guidance/gid-ta10143/documents/scope-consultation-comments-and-responses
I'll provide a quick synopsis of the things that stood out to me.
First... all comments on this pdf were provided by the Association of British Neurologists (ABN).
Second, first there is a topic, then a topic question, then a comment from the ABN, and then an action.
Topic: Timing
Question:
What is the relative urgency of this appraisal to the NHS?
Comment:
Given the current absence of phase III trials for DCVaxL but the pending results of a phase III RCT trial, this NICE single technology appraisal would be better completed following publication of that study.
Action:
Comment noted. NICE aims to publish guidance on cancer drugs within 90 days of marketing authorisation. Any requirements for potential delays will be taken into account as appropriate.
Topic: Additional Comments
Question: None - this is just for additional comments
Comments:
Could/was DCVaxL for GBM (and this remit therefore) covered in the Primary brain tumours and cerebral metastases. NICE clinical guideline which is currently in development? And therefore is this separate remit required at this point?
Action:
Comment noted. This remit is specifically for a technology appraisal of DCVaxL for GBM. NICE has committed to appraising all new cancer drugs and new indications for existing cancer drugs. Therefore, a technology appraisal of this drug is considered necessary at this stage.
Topic: Innovation
Questions:
1.
Do you consider the technology to be innovative in its potential to make a significant and substantial impact on health-related benefits and how it might improve the way that current need is met (is this a ‘step-change’ in the management of the condition)?
2.
Do you consider that the use of the technology can result in any potential significant and substantial health-related benefits that are unlikely to be included in the QALY calculation? Please identify the nature of the data which you understand to be available to enable the Appraisal Committee to take account of these benefits.
Comments:
1.
Yes – if it shown to work in a phase III clinical trial (still awaited)
2.
Data is currently awaited for phase III RCT. Data is available for phase I and II trials.
Action:
Comment noted. The committee will consider the innovative nature of the technology at the time of the appraisal. No changes to the scope are needed
https://www.nice.org.uk/guidance/gid-ta10143/documents/scope-consultation-comments-and-responses
So... what to make of all that? Well, it seems the ABN thinks the appraisal should be completed following the publication of the P3 unblinded results. However, the action is to note first, that they plan to publish guidance within 90 days of marketing authorization, and second, they will take this into consideration as appropriate. Then pertaining to the second set of comments, the action is that NICE considers the technology appraisal necessary at this stage.
Now on this link - NICE indicates that they have a provisional schedule to hold a Committee Meeting for DCVax-L on
November 8, 2018.
https://www.nice.org.uk/guidance/indevelopment/gid-ta10143
That's a new development as well.
So all in all, it seems that NICE at least feels that now is the appropriate time to move forward on the Single Technology Appraisal (STA) on DCVax. I will note that ABN didn't comment that the process shouldn't begin now, simply that it was their recommendation that it should be completed after publication of the unblinded P3 data.
Recent NWBO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM